INTRODUCTION {#sec1-1}
============

Cancer is commonly defined by irregular cellular proliferation. In cancerous cells, there is an abnormal response to the checkpoint mechanisms regulating cell division; hence, the cells remain to divide until they finally kill the host ([@ref1]). Although current anti-cancer compounds make a significant contribution in cancer treatment there is a continuing search to improve anticancer pharmaceuticals ([@ref2]). There are many reports about the incidence and prevalence of mortality from cancer ([@ref3]). Quinazoline derivatives are an important class of compounds in medicinal chemistry with a wide variety of biological activities such as antimicrobial, antifungal, antiviral, antiinflammatory, anticonvulsant, analgesic, antitubercular, anti-HIV, and anticancer activities ([@ref13]). Interests in quinazolines as anticancer agents have further increased since the discovery of raltitrexed. These compounds exert their antitumor activity through inhibition of the DNA repair enzyme system ([@ref14]). Quinazoline is a nitrogen-containing heterocyclic scaffold which is also known as 5,6-benzopyrimidine or benzo pyrimidine ([@ref5]).

In this regard a vast number of quinazoline derivatives have been synthesized to provide synthetic drugs as more effective medicines ([@ref5]). Amongst the different quinazolinone categories ([Fig. 1](#F1){ref-type="fig"}), 2-substituted-4(3H)- quinazolinones is being studied extensively as an important pharmacophore which are the most prevalent pharmaceutical agents ([@ref7][@ref8]). The present study aimed to synthesize and evaluate the biological activity of some new quinazoline derivatives as potential cytotoxic agents. In continuation of our previous studies ([@ref15][@ref16][@ref17]), here a new series of quinazoline compounds were synthesized and evaluated against three human cancer cell lines, MCF-7 (breast cancer), A549 (lung cancer), and SKOV3 (ovarian cancer) using the colorimetric MTT cytotoxic assay.

![Different quinazoline scaffolds](RPS-14-115-g001){#F1}

MATERIALS AND METHODS {#sec1-2}
=====================

All chemicals and solvents were purchased from Merck (Germany). Infrared (IR) spectra were run on a Shimadzu *FTIR-8300* spectrophotometer (USA), proton nuclear magnetic resonance (^1^H-NMR, 300 MHz), and carbon-13-NMR (^13^C-NMR, 75 MHz) were run on a Bruker advanced *DPX-250*, *FT-NMR* spectrometer (Germany). Mass spectra were recorded on an Agilent 7890A-GC, Agilent 7000 Series Triple Quad-MS spectrometer (USA).

 {#sec2-1}

### General procedure for the synthesis of dibromo anthranilamide {#sec3-1}

A mixture of 2-aminobenzamide and N-bromosuccinimide in chloroform was s tirred at room temperature for 4 h. The solvent was removed by vacuum evaporation, and the crude product was purified by column chromatography over silica gel to provide dibromoanthranilamide ([Scheme 1](#F2){ref-type="fig"}).

![Synthesis of dibromo anthranilamide.](RPS-14-115-g002){#F2}

### General procedure for the synthesis of dibromo-2-arylquinazolinone (**1a**-**1g**) {#sec3-2}

A mixture of 2-amino-3,5-dibromo-benzamide and appropriate aromatic aldehyde in ethanol were refluxed for 3 h. Then CuCl~2~ (3 eq) was added and refluxed for another 3 h at 70 °C. The progress of the reaction was checked by thin layer chromatography (TLC). After completion the reaction, the mixture was filtered, washed by cold ethanol and then recrystallized with hot ethanol to get the pure final compounds ([Scheme 2](#F3){ref-type="fig"}).

![Synthesis of dibromo-2-arylquinazolinone (1a-1g).](RPS-14-115-g003){#F3}

### Synthesis details and spectral data of products {#sec3-3}

6,8-dibromo-2-styrylquinazolin-4(3H)-one (1a)

2-Amino-3,5 - dibromobenzamide (0.880 g) was reacted with cinamaldehyde (0.476 g). IR (KBr) ν (cm^-1^): 3367 (N-H stretch), 3173-3074 (C-H stretch, aromatic), 2919 (C-H stretch, aliphatic), 1672 (C=O amid), 1581 (N-H bending), 691 (C-Br stretch). ^1^H-NMR (300 MHz, DMSO-*d~6~*): δ (ppm): 12.81 (s, 1H, NH), 8.43 (d, 1H, *J* = 1.8 Hz, aromatic), 8.25 (d, 1H, *J* = 1.8 Hz, aromatic), 8.08 (d, 1H, *J* = 12 Hz, alkene), 7.75-7.77 (m, 2H, aromatic), 7.51-7.59 (m, 3H, aromatic), 7.08 (1H, d, *J* = 12 Hz, alkene). ^13^C-NMR (75 MHz, DMSO-*d~6~*): δ (ppm): 160.3, 152.5, 145.7, 139.8, 139.6, 134.6, 130.1, 129.2, 127.8, 126.7, 123.6, 123.2, 120.7, 118.2. MS m/z (%): 408 (40) \[M^+4^\], 406 (80) \[M^+2^\], 405.0 (100), 404.0 (37) \[M^+^\], 276.9 (27), 122.5 (24), 103.0 (33), 77.1 (50).

6,8-dibromo-2-(3-flourophenyl)-quinazoline- 4(3H)-one (1b)

2-Amino-3,5-dibromobenzamide (0.880 g) was reacted with 3-flourobenzaldehyde (0.447 g). IR (KBr) *ν* (cm^-1^): 3449 (N-H stretch), 3162-3094 (C-H stretch, aromatic), 1674 (C=O amid), 1574 (N-H bending).^1^H-NMR (300 MHz, DMSO-*d~6~*): δ (ppm): 13.04 (s, 1H, NH), 8.45 (s, 1H, aromatic), 8.28 (s, 1H, aromatic), 8.18 (d, *J* = 6 Hz, 1H, aromatic), 8.11 (d, *J* = 7.8 Hz, 1H, aromatic), 7.71 (q, *J* = 5.7, Hz, 1H, aromatic), 7.56 (t, *J* = 6 Hz, 1H, aromatic). ^13^C-NMR (75 MHz, DMSO-*d~6~*): δ (ppm): 163.3, 160.8, 152.0, 145.1, 139.7, 134.4, 130.9, 127.9, 124.2, 123.7, 119.0, 118.7, 114.8, 114.6. MS m/z (%): 400 (47) \[M^+4^\], 398 (100) \[M^+2^\], 396 (47) \[M^+^\], 277 (100), 122.1 (53), 95.1 (67), 88.0 (32), 75.1 (30).

6,8-dibromo-2-(4-bromophenyl) quinazolin- 4(3H)-one (1c)

2-Amino-3,5-dibromobenzamide (0.880 g) was reacted with 4-bromobenzaldehyde (0.666 g). IR (KBr) *ν* (cm^-1^): 3390 (N-H stretch), 3171-3072 (C-H stretch, aromatic), 1683 (C=O, amid), 1558 (N-H bending). ^1^H-NMR (300 MHz, DMSO-*d~6~*): δ (ppm): 8.97 (d, *J* = 2.4 Hz, 1H, NH), 7.89 (d, 1H, *J* = 1.8 Hz, aromatic), 7.76 (d, 1H, *J* = 1.8 Hz, aromatic), 7.65 (d, 2H, *J* = 6.6 Hz, aromatic), 7.42 (d, 2H, *J* = 6.6 Hz, aromatic). ^13^C-NMR (75 MHz, DMSO-*d~6~*): δ (ppm): 161.0, 143.2, 141.5, 137.9, 131.3, 130.0, 129.2, 128.2, 121.4, 117.8, 108.8, 108.0. MS m/z (%): 462 (15) \[M^+6^\], 460 (20) \[M^+4^\], 458 (10) \[M^+2^\], 456 (5) \[M^+^\], 305 (100), 278 (27), 76.0 (22), 44.2 (23).

6,8-dibromo - 2 - (3-bromophenyl) quinazolin- 4(3H)-one (1d)

2-Amino-3,5-dibromobenzamide (0.880 g) was reacted with 3-bromobenzaldehyde (0.666 g). IR (KBr) *ν* (cm^-1^): 3246 (N-H stretch), 3178 (C-H stretch, aromatic), 1685 (C=O, amid), 1559 (N-H bending). ^1^H-NMR (300 MHz, DMSO-*d~6~*): δ (ppm): 12.93-12.94 (m, 1H, NH), 8.17-8.44 (m, 3H, aromatic), 7.83 (m, 1H, aromatic), 7.51-7.74 (m, 2H, aromatic). ^13^C-NMR (75 MHz, DMSO-*d~6~*): δ (ppm): 161.0, 149.1, 144.1, 139.7, 137.5, 134.5, 130.8, 127.8, 127.0, 126.9, 124.9, 123.7, 121.9, 118.9. MS m/z (%):462 (25) \[M^+6^\], 460 (70) \[M^+4^\], 458 (65) \[M^+2^\], 456 (25) \[M^+^\], 380.0 (90), 277(100), 199.0 (99), 170 (30), 155.0 (42), 102.1 (35), 88.0 (42), 75.1 (72), 63.2 (31), 50.1 (25).

6,8- dibromo - 2 - (4-nitrophenyl) quinazolin- 4(3H)-one (1e)

2-Amino-3,5-dibromobenzamide (0.880 g) was reacted with 4-nitrobenzaldehyde (0.544 g). IR (KBr) *ν* (cm^-1^): 3155 (N-H stretch), 3074-3011 (C-H stretch, aromatic), 1681 (C=O, amid), 1585 (N-H bending), 1519, 1354 (NO~2~ stretch). ^1^H-NMR (300 MHz, DMSO-*d~6~*): δ (ppm): 13.23 (s, 1H, NH), 8.46-8.50 (m, 5H, aromatic), 8.30-8.32 (m, 1H, aromatic). ^13^C-NMR (75 MHz, DMSO-*d~6~*): δ (ppm): 160.8, 151.9, 149.2, 145.1, 139.8, 138.1, 137.6, 129.5, 129.4, 128.0, 127.3, 123.7, 123.6, 119.5. MS m/z (%): 427 (55) \[M^+4^\], 425 (100) \[M^+2^\], 423 (50) \[M^+^\], 395 (21), 345.1 (60), 305.0 (61), 277 (67), 192.0 (35), 170.0 (32), 119.0 (20), 103.2 (44), 88.0 (45), 76.2 (68), 63.1 (28), 50.1 (25).

6,8-dibromo-2-(3-methoxyphenyl) quinazolin- 4(3H)-one (1f)

2-Amino-3,5-dibromobenzamide (0.880 g) was reacted with 3-methoxybenzaldehyde (0.490 g). IR (KBr) *ν* (cm^-1^): 3446 (N-H stretch), 3194-3093 (C-H stretch, aromatic), 2837 (C-H stretch aliphatic), 1672 (C=O, amid), 1571 (N-H bending), 1237 (C-O stretch). ^1^H-NMR: δ (ppm): 13.01 (s, 1H, NH), 8.47 (d, 1H, *J* = 1.8 Hz, aromatic), 8.30 (d, 1H, *J* = 1.8 Hz, aromatic), 7.96 (d, 1H, *J*=6 Hz, aromatic), 7.91-7.92 (m, 1H, aromatic), 7.59 (t, 1H, *J*=6 Hz, aromatic), 7.29 (dd, 1H, *J* = 6, 1.8 Hz, aromatic), 3.95 (s, 3H, OCH~3~). ^13^C-NMR (75 MHz, DMSO-*d~6~*): δ: 160.9, 159.3, 153.0, 145.3, 139.7, 133.4, 129.9, 127.8, 123.7, 123.6, 120.3, 118.7, 117.9, 112.9, 55.4. MS m/z (%): 412 (3) \[M^+4^\], 410 (5) \[M^+2^\], 408 (2) \[M^+^\], 171.1 (11), 91.0 (10), 77.1 (10), 40.1 (100).

6,8-dibromo-2-(4-benzyloxyphenyl) quinazolin- 4(3H)-one (1g)

2-Amino-3,5-dibromobenzamide (0.880 g) was reacted with 4-benzyloxybenzaldehyde (0.764 g). IR (KBr) *ν* (cm^-1^): 3327 (N-H Stretch), 3194-3032 (C-H stretch, aromatic), 2942 (C-H stretch aliphatic), 1666 (C=O, amid), 1563 (N-H bending), 1237 (C-O stretch). ^1^H-NMR: δ (ppm): 12.85 (s, 1H, NH), 8.40 (d, 1H, *J* = 1.8 Hz, aromatic), 8.32 (d, 2H, *J* = 6.9 Hz, aromatic), 8.24 (d, 1H, *J* = 1.8 Hz, aromatic), 7.54-7.56 (m, 2H, aromatic), 7.48 (t, 2H, *J* = 5.7 Hz, aromatic), 7.42-7.44 (m, 1H, aromatic), 7.27 (d, 2H, *J* = 6.9 Hz, aromatic), 5.29 (s, 2H, CH~2~-benzyl). ^13^C NMR (75 MHz, DMSO-*d~6~*): δ (ppm): 161.4, 160.9, 152.8, 145.5, 139.6, 136.5, 129.8, 128.5, 128.0, 127.8, 127.7, 124.3, 123.4, 123.2, 118.0, 114.9, 69.5. MS m/z (%): 484.1 (1) \[M^+^\], 337.0 (25), 169.0 (47), 151.0 (60), 124.0 (93), 94.0 (100), 44.1 (97).

### Cell lines and cell culture {#sec3-4}

Three human cell lines (MCF-7, A549, SKOV3) were obtained from the National Cell Bank of Iran (NCBI, Pasteur Institute, Tehran, I.R. Iran) and were cultured under aseptic conditions in the complete culture media containing Roswell Park Memorial Institute (RPMI) 1640 medium (Biosera, France), 10% fetal bovine serum (FBS; Gibco, USA), and 1% penicillin/streptomycin (Biosera, France) at 37 °C in a humidified CO~2~ incubator. Following 70-80 confluency, the cells were trypsinized using 25% trypsin-EDTA solution (Biosera, France), were counted and then seeded in 96-well cell culture microplate in a density of 10 × 10^3^ cells per well in 100 μL complete culture medium for MTT assay.

### Cytotoxicity assay {#sec3-5}

The cytotoxic effects of the synthesized 2-aryldibromoquinazolinones on these cell lines were evaluated using the 3-(4,5- dimethylthiazolyl) - 2,5 - diphenyltetrazolium bromide (MTT) standard assay as previously described. Briefly, following 24 h incubation to recover and reattach, the seeded cells were treated with different concentrations of each compound in triplicate manner. The compounds were first solved in high-grade DMSO and then diluted in culture medium to make different concentrations (31.25-1000 μM).

To prevent bystander cytotoxic effect, the final concentration of DMSO was kept less than 0.1%. cisplatin with different concentrations was also used as positive control. Three wells were left without treatment as cell-based negative controls, and three wells of cell culture medium alone were also considered as blanks. Following 72 h incubation at 37 °C in a humidified CO~2~ incubator, the media were completely removed and 100 μL of RPMI-1640 containing 0.5 mg/mL MTT solution were added to the wells including controls, incubated for more 3 h at room temperature, and checked periodically for the appearance of purple formazan precipitates. The media containing MTT were then completely discarded and 100 μL DMSO was added to each well to dissolve the formazan crystals. Following 30 min incubation at 37 °C in the dark, the absorbance of each well was measured at 495 nm with a microplate ELISA reader.

### Data analysis {#sec3-6}

Excel 2013 and CurveExpert 1.4. were used to calculate and analyze the data. The inhibitory concentration (IC) for each compound was calculated and reported using following equation:

![](RPS-14-115-g004.jpg)

where, OD is optical density. In this equation the differences between the OD of the tested samples and blank were divided by those of the negative controls (untreated wells) and multiplied by 100 to obtain the percentage of viable cells. Then this value was subtracted from 100 to calculate the IC.

A plot of the IC *vs* concentration was depicted for each compound using Curve Expert 1.4 and an IC50, indicating the 50% growth inhibition of the cells was obtained for each compound. Data are presented as mean ± SD.

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Chemistry {#sec3-7}

Seven derivatives of 2-aryldibromoquinazolinones were prepared with desirable yields. The identity of the final products was checked by melting points and different spectroscopic methods. The characteristic of the synthesized compounds are shown in [Table 1](#T1){ref-type="table"}.

###### 

Synthesized 2-aryldibromoquinazolinones derivatives and their chemical properties

  ID Code                                                     Chemical structures        Chemical formula and names   MW ^(^g^/mol)^   MP (°C)   Yield (%)
  ----------------------------------------------------------- -------------------------- ---------------------------- ---------------- --------- -----------
  **1a**                                                      ![](RPS-14-115-g005.jpg)   C16H10Br2N2O                                            
  6,8-dibromo-2-styrylquinazolin-4(*3H*)-one                  404                        331-334                      85                         
  **1b**                                                      ![](RPS-14-115-g006.jpg)   C~14~H~7~Br~2~FN~2~O                                    
  6,8-dibromo-2-(3-fluorophenyl)quinazoline-4(*3H*)-one       396                        332-334                      90                         
  **1c**                                                      ![](RPS-14-115-g007.jpg)   C~14~H~7~Br~3~N~2~O                                     
  6,8-dibromo-2-(3-bromophenyl)quinazolin-4(*3H*)-one         456                        346-349                      85                         
  **1d**                                                      ![](RPS-14-115-g008.jpg)   C~14~H~7~Br~3~N~2~O                                     
  6,8-dibromo-2-(4-bromophenyl)quinazolin-4(*3H*)-one         456                        382-385                      87                         
  **1e**                                                      ![](RPS-14-115-g009.jpg)   C~14~H~7~Br~2~N~3~O~3~                                  
  6,8-dibromo-2-(4-nitrophenyl)quinazolin-4(3H)-one           423                        345-349                      85                         
  **1f**                                                      ![](RPS-14-115-g010.jpg)   C15H10Br2N2O2                                           
  6,8-dibromo-2-(3-methoxyphenyl)quinazolin-4(*3H*)-one       408                        302-304                      86                         
  **1g**                                                      ![](RPS-14-115-g011.jpg)   C~21~H~14~Br~2~N~2~O~2~                                 
  2-(4-(benzyloxy)phenyl)-6,8-dibromoquinazolin-4*(3H*)-one   484                        256-259                      80                         

MW, molecular weight; MP, melting point.

### Cytotoxic effects of quinazolinone derivatives {#sec3-8}

The cytotoxic effects of the synthesized 2-aryldibromoquinazolinone derivatives were evaluated on three cancerous cell lines of MCF-7, A549, and SKOV3. Amongst tested compounds, **1f** and **1g** were considered most active compounds of this series as they exhibited higher toxicities against all examined cancer cell lines with IC~50~ of 101.37 ± 12.20, 124.5 ± 20.51, and 125 ± 7.07 for MCF-7, A549, and SKOV3, respectively. Amongst other compounds, ***1b*** and ***1c*** showed cytotoxicity only on MCF-7 cell line whilst the others showed no cytotoxic effects against examined cell lines ([Table 2](#T2){ref-type="table"}).

###### 

*In vitro* cytotoxic activity of 2-aryldibromoquinazolinones against cancer cell lines Data are presented as mean ± SD.

  ID Code     IC50 (μM)                       
  ----------- --------------- --------------- --------------
  **1a**      \> 1000         \> 1000         \> 1000
  **1b**      201.5 ± 26.2    \> 1000         \> 1000
  **1c**      599.5 ±136.5    \> 1000         \> 1000
  **1d**      \> 1000         \> 1000         \> 1000
  **1e**      \> 1000         \> 1000         \> 1000
  **1f**      101.4 ± 12.20   124.5 ± 20.51   125 ± 7.07
  **1g**      156 ± 22.63     290 ± 14.14     909 ± 187
  Cisplatin   61.56 ± 0.98    50.81 ± 3.10    43.81 ± 3.79

DISCUSSION {#sec1-4}
==========

Quinazoline derivatives exhibits a class of compounds with diverse spectrum of therapeutic potential ([@ref18][@ref19]). A vast number of quinazoline derivatives have been recently synthesized to design more effective medicaments. Various aromatic groups with electron-withdrawing and electron-donating substituents at various positions of the quinazoline ring were also considered ([@ref20]). Chandrika *et al.* synthesized some quinazoline derivatives with iodine substitution on the quinazoline ring exhibiting desirable anticancer activity on U937 leukemia cell line ([@ref9]). Some brominated derivatives of quinazoline were also synthesized by DiMauro *et al.* to bind to lymphocyte-specific kinase (Lck) as anti-inflammatory agents ([@ref4]). In addition, several reports for synthesis of 4-chloroquinazoline and 6-bromoquinazoline as anticancer and antimicrobial agents have been reported ([@ref21][@ref22][@ref23]). Here we reported the synthesis of some 2-aryldibromoquinazolinone derivatives. The cytotoxic activities of these derivatives were also assessed against three cancerous cell lines. The results collectively illustrated that **1f** and **1g** had satisfactory anti-tumor activities especially on breast (MCF-7) and lung (A549) carcinoma cell lines. Based on MTT results and chemical features, the activity can be related to the chemical structure of the compounds. As it is observed in [Table 1](#T1){ref-type="table"}, both **1f** and **1g** contain alkoxy groups (methoxyphenyl in **1f** and benzyloxyphenyl in 1g) in their structures. These alkoxy groups at 2 position of the quinazoline ring increased the cytotoxic activities. According to our results compounds having electron-withdrawing groups such as halogens or nitro group at para position of the benzene ring displayed no cytotoxic effectwhile, compounds having halogen groups at meta position of the benzene ring, (**1b** and **1c**) exhibited some cytotoxic activities.

CONCLUSION {#sec1-5}
==========

It could be concluded that the presence of electron-donating groups such as methoxy or benzyloxy substitutions remarkably increases the cytotoxic activity of the **1f** and **1g**. Further evaluation of these compounds revealed that substitution of a methoxy group at position 3 of the aromatic ring of aldehyde, could improve the cytotoxic activity than a benzyloxy group at position 4 of this ring. Compound **1f** with the highest potency could be introduced as a candidate for further *in vitro* and *in vivo* anticancer studies.
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